

On page 1, line 2, please delete "Attorney Docket No.: 02-106720US" and insert therefor --Attorney Docket No.: 0169.310US--.

On page 1, line 3, please delete "Client Reference No.: 0169.310".

In the Figures.

Applicants also amend the formal drawings submitted with a Letter to Official Draftsperson on November 26, 2001 for Figures 8A, 8B, 9G, and 9H to correct several inadvertent typographical errors introduced when the formal drawings were prepared. The changes to the formal drawings corresponding to Figures 8A, 8B, 9G, and 9H are shown in red on copies of the figures enclosed herewith. The following errors were identified as introduced in the formal drawings, as compared to the drawings originally filed. In the formal drawings submitted for Figures 8A and 8B, the complete name of each clone -- "CTLA-4BP-5x4-12C" and "CD28BP-15" -- is incomplete. In the formal drawing submitted for Figure 8A, the dashed line indicating the predicted transmembrane domain is to begin at the leucine amino acid residue (L) -- one residue before the proline residue, as shown in the originally filed informal drawing for Figure 8A. In the formal drawing submitted for Figure 8B, the dashed line indicating the predicted transmembrane domain is to begin at the leucine amino acid residue (L), as shown in the originally filed Figure 8B.

In the formal drawings submitted for Figures 9G-9H, the histograms for CTLA-4BP 5x4-12c and hB7-1 were inadvertently not shown in gray, as in the originally filed Figures 9G-9H and as indicated in the specification, at page 201, line 30 to page 202, line 2.

These corrections are consistent with the informal drawings for Figures 8A, 8B, 9G, and 9H that were originally filed with the application on June 22, 2001. No new matter is introduced by these amendments. If the Examiner approves of these changes, Applicants will re-submit the corrected formal drawings to the Official Draftsperson.

In the Claims:

As indicated below, please cancel original claims 1-258 without prejudice to subsequent renewal in the present application or filing in a continuation or divisional application. Please add new claims 259-381 as follows:

259. (New) An isolated or recombinant polypeptide comprising an extracellular domain, said extracellular domain comprising an amino acid sequence having at least about 91% sequence identity to a subsequence of the polypeptide sequence set forth in SEQ ID NO:66, wherein